Jena, July 28, 2010 — Analytik Jena AG (Frankfurt DE0005213508, Prime Standard: AJA) today announced its preliminary sales and earnings figures for the first nine months of the current 2009/2010 financial year. The Thuringia-based provider of analytical instrumentation technology generated an operating result (EBIT) of EUR 3.2 m on the back of sales of EUR 59.6 m. Earnings per share amounted to EUR 0.47.

Based on the current course of business, the Company expects to record EBIT of around EUR 5.0 m and earnings per share of around EUR 0.60 for the financial year as a whole, down on its initial forecasts.

This adjustment is due to the sustained difficult development in the Optics segment, which has not enjoyed the recovery that was expected. The Company also reported non-recurring effects from the closure of CyBio Japan in the past quarter, as well as a sharp increase in costs for the establishment of a uniform international sales structure in the Life Science sector.

The Company still expects to achieve record sales of around EUR 80.0 m and intends to recommend the distribution of a dividend to the Supervisory Board at its meeting in December 2010 to adopt the annual financial statements.

This information is based on preliminary key financial figures. The complete figures for the first nine months of the 2009/2010 financial year will be announced on August 12, 2010.

Contact:
Dana Schmidt
Analytik Jena AG
Konrad-Zuse-Strasse 1
07745 Jena | Germany
Phone: +49 (0) 36 41  77-92 81
E-mail: ir@analytik-jena.com